AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 20172912 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified Task Force Criteria for ARVC/D diagnosis
Number of subjects: 0
Study 20172912 — intervention group
Group type: EXPERIMENTAL
Intervention: Emerging diagnostic modalities and genetic advances
Number of subjects: 0
Study 20173748 — intervention group
Group type: EXPERIMENTAL
Intervention: FAM13A variants (specifically rs7671167)
Number of subjects: 2940
Study 20173748 — intervention group
Group type: COMPARATOR
Intervention: Control group (1,380 controls)
Number of subjects: 2940
Study 20173748 — intervention group
Group type: EXPERIMENTAL
Intervention: Replication in one case-control group (n = 1,006) and two family-based cohorts (n = 3,808)
Number of subjects: 2940
Study 20174766 — intervention group
Group type: EXPERIMENTAL
Intervention: Bone marrow (BM)-derived mononuclear cells administered to patients with limb ischaemia
Number of subjects: 0
Study 20174766 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous stem cell therapy for ischaemic peripheral disease
Number of subjects: 0
Study 20176858 — intervention group
Group type: EXPERIMENTAL
Intervention: ACSL1 rs9997745 GG homozygotes
Number of subjects: 1754
Study 20176858 — intervention group
Group type: COMPARATOR
Intervention: Low-fat diet (<35% energy) or high-PUFA diet (>5.5% energy)
Number of subjects: 1754
Study 20176990 — intervention group
Group type: EXPERIMENTAL
Intervention: Physician-directed patient self-management of left atrial pressure
Number of subjects: 40
Study 20178624 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-centered quality improvement interventions (communication skills training and care management focused on explanatory models, socio-cultural barriers, and treatment preferences)
Number of subjects: 132
Study 20178624 — intervention group
Group type: COMPARATOR
Intervention: Standard quality improvement interventions (academic detailing about depression guidelines and disease-oriented care management)
Number of subjects: 132
Study 20178723 — intervention group
Group type: EXPERIMENTAL
Intervention: PFA-100 collagen/epinephrine (CEPI)
Number of subjects: 56
Study 20178723 — intervention group
Group type: EXPERIMENTAL
Intervention: PFA-100 collagen/adenosine diphosphate (CADP)
Number of subjects: 56
Study 20178723 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-biopsy hematoma formation on US
Number of subjects: 56
Study 20178723 — intervention group
Group type: EXPERIMENTAL
Intervention: Macroscopic hematuria
Number of subjects: 56
Study 20178723 — intervention group
Group type: EXPERIMENTAL
Intervention: Packed red blood (PRBC) transfusions
Number of subjects: 56
Study 20178723 — intervention group
Group type: EXPERIMENTAL
Intervention: PRBC transfusions
Number of subjects: 56
Study 20179285 — intervention group
Group type: EXPERIMENTAL
Intervention: Light transmittance aggregometry
Number of subjects: 1069
Study 20179285 — intervention group
Group type: EXPERIMENTAL
Intervention: Verify Now
Number of subjects: 1069
Study 20179285 — intervention group
Group type: EXPERIMENTAL
Intervention: Platelet works
Number of subjects: 1069
Study 20179285 — intervention group
Group type: EXPERIMENTAL
Intervention: Innovance PFA P2Y
Number of subjects: 1069
Study 20179285 — intervention group
Group type: EXPERIMENTAL
Intervention: IMPACT-R
Number of subjects: 1069
Study 20179285 — intervention group
Group type: EXPERIMENTAL
Intervention: Siemens PFA Collagen/ADP
Number of subjects: 1069
Study 20179614 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional laboratory upper limit of normal (ULN) criteria
Number of subjects: 45
Study 20179614 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified ALT ULN criteria
Number of subjects: 45
Study 20179614 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall
Number of subjects: 45
Study 20180156 — intervention group
Group type: EXPERIMENTAL
Intervention: Focus groups on lifestyle modification and disease management
Number of subjects: 34
Study 20180156 — intervention group
Group type: EXPERIMENTAL
Intervention: Focus groups on management and education for diabetes and hypertension
Number of subjects: 34
Study 20180156 — intervention group
Group type: EXPERIMENTAL
Intervention: Interactive discussion groups
Number of subjects: 34
Study 20180805 — intervention group
Group type: EXPERIMENTAL
Intervention: Axitinib 5 mg single dose followed by continuous 5 mg twice-daily dosing
Number of subjects: 12
Study 20180805 — intervention group
Group type: EXPERIMENTAL
Intervention: Axitinib 5 mg twice-daily
Number of subjects: 12
Study 20181032 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive implementation strategy (education and tools for risk calculation, interpretation, and communication; patient decision aids)
Number of subjects: 18
Study 20181032 — intervention group
Group type: COMPARATOR
Intervention: Common implementation strategy (dissemination of the guideline)
Number of subjects: 18
Study 20181032 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive implementation strategy
Number of subjects: 18
Study 20181032 — intervention group
Group type: COMPARATOR
Intervention: Common implementation strategy
Number of subjects: 18
Study 20181120 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-session early psychological intervention
Number of subjects: 99
Study 20181120 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 99
Study 20181282 — intervention group
Group type: EXPERIMENTAL
Intervention: Latanoprost once daily (evening)
Number of subjects: 572
Study 20182862 — intervention group
Group type: EXPERIMENTAL
Intervention: Fasting Plasma Glucose (FPG)
Number of subjects: 6006
Study 20182862 — intervention group
Group type: EXPERIMENTAL
Intervention: HbA(1c)
Number of subjects: 6006
Study 20182862 — intervention group
Group type: EXPERIMENTAL
Intervention: 2h post-OGTT Plasma Glucose (2hPG)
Number of subjects: 6006
Study 20182862 — intervention group
Group type: EXPERIMENTAL
Intervention: High-risk HbA(1c) criteria (6.0-6.5%)
Number of subjects: 6006
Study 20182862 — intervention group
Group type: COMPARATOR
Intervention: OGTT
Number of subjects: 6006
Study 20182862 — intervention group
Group type: EXPERIMENTAL
Intervention: FPG and HbA(1c) levels
Number of subjects: 6006
Study 20184584 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical excision for anal margin carcinomas
Number of subjects: 446
Study 20184584 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined chemoradiotherapy for anal canal carcinomas
Number of subjects: 446
Study 20184584 — intervention group
Group type: EXPERIMENTAL
Intervention: High-grade AIN progression to invasive cancer
Number of subjects: 446
Study 20184584 — intervention group
Group type: EXPERIMENTAL
Intervention: HPV analysis in anal carcinoma
Number of subjects: 446
Study 20184584 — intervention group
Group type: EXPERIMENTAL
Intervention: HPV analysis in anal margin carcinoma
Number of subjects: 446
Study 20184584 — intervention group
Group type: EXPERIMENTAL
Intervention: HPV analysis in anal swabs
Number of subjects: 446
Study 20184783 — intervention group
Group type: EXPERIMENTAL
Intervention: Sibutramine 10 mg once daily for 6 weeks
Number of subjects: 10742
Study 20184807 — intervention group
Group type: EXPERIMENTAL
Intervention: Antipsychotic-naive first-episode schizophrenia patients
Number of subjects: 38
Study 20184807 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 38
Study 20186499 — intervention group
Group type: EXPERIMENTAL
Intervention: Stand-alone e-prescribing system with clinical decision support
Number of subjects: 30
Study 20186499 — intervention group
Group type: COMPARATOR
Intervention: Paper-based prescribing (control)
Number of subjects: 30
Study 20187924 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine (20 to 60 mg; mean dose = 45.8 mg/day; SD = 15.1) for 52 weeks
Number of subjects: 570
Study 20187924 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 52 weeks
Number of subjects: 570
Study 20188071 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum miR-146a
Number of subjects: 100
Study 20188071 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum miR-223
Number of subjects: 100
Study 20188071 — intervention group
Group type: EXPERIMENTAL
Intervention: IL-6
Number of subjects: 100
Study 20188202 — intervention group
Group type: EXPERIMENTAL
Intervention: NK cell-enriched donor lymphocyte infusions (DLIs)
Number of subjects: 30
Study 20188503 — intervention group
Group type: EXPERIMENTAL
Intervention: Transfemoral aortic valve implantation (TAVI) using the CoreValve prosthesis.
Number of subjects: 30
Study 20188504 — intervention group
Group type: EXPERIMENTAL
Intervention: Iodine-123 meta-iodobenzylguanidine ((123)I-mIBG) imaging with heart/mediastinum uptake ratio (H/M)
Number of subjects: 961
Study 20188504 — intervention group
Group type: EXPERIMENTAL
Intervention: Iodine-123 meta-iodobenzylguanidine ((123)I-mIBG) imaging
Number of subjects: 961
Study 20189159 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% mecamylamine topically twice daily for 12 weeks
Number of subjects: 23
Study 20189513 — intervention group
Group type: EXPERIMENTAL
Intervention: Third Eye Retroscope (TER)
Number of subjects: 298
Study 20189674 — intervention group
Group type: EXPERIMENTAL
Intervention: PEG-IFN alfa-2b plus RBV
Number of subjects: 70
Study 20190585 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced vaccine education intervention with pictures and application vignettes and enhanced risk-reduction counseling (3 one-on-one counseling sessions)
Number of subjects: 311
Study 20190585 — intervention group
Group type: COMPARATOR
Intervention: Standard conditions
Number of subjects: 311
Study 20190673 — intervention group
Group type: EXPERIMENTAL
Intervention: Tdap vaccination (Boostrix GlaxoSmithKline)
Number of subjects: 13427
Study 20191490 — intervention group
Group type: EXPERIMENTAL
Intervention: Strength training
Number of subjects: 273
Study 20191490 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-management
Number of subjects: 273
Study 20191490 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined program
Number of subjects: 273
Study 20191499 — intervention group
Group type: EXPERIMENTAL
Intervention: DHEA substitution (50 mg/day)
Number of subjects: 107
Study 20191499 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 107
Study 20191935 — intervention group
Group type: EXPERIMENTAL
Intervention: Gaboxadol 15 mg
Number of subjects: 310
Study 20191935 — intervention group
Group type: EXPERIMENTAL
Intervention: Gaboxadol 10 mg
Number of subjects: 310
Study 20191935 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 310
Study 20194481 — intervention group
Group type: EXPERIMENTAL
Intervention: Citalopram treatment
Number of subjects: 1953
Study 20194866 — intervention group
Group type: EXPERIMENTAL
Intervention: Ofatumumab (300 mg for dose 1; 2000 mg for doses 2 to 12) administered as eight weekly infusions followed by four monthly infusions over 24 weeks
Number of subjects: 138
Study 20194866 — intervention group
Group type: EXPERIMENTAL
Intervention: Ofatumumab
Number of subjects: 138
Study 20197513 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravascular ultrasound (IVUS) assessment
Number of subjects: 140
Study 20200024 — intervention group
Group type: EXPERIMENTAL
Intervention: Pazopanib 800 mg daily on 4-week cycles
Number of subjects: 35
Study 20202270 — intervention group
Group type: EXPERIMENTAL
Intervention: Falls (1+ falls)
Number of subjects: 109
Study 20202270 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple falls
Number of subjects: 109
Study 20202270 — intervention group
Group type: EXPERIMENTAL
Intervention: Fallers (1+ falls)
Number of subjects: 109
Study 20202270 — intervention group
Group type: EXPERIMENTAL
Intervention: Health service costs
Number of subjects: 109
Study 20202270 — intervention group
Group type: EXPERIMENTAL
Intervention: Specific health services
Number of subjects: 109
Study 20202270 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk factors for falls
Number of subjects: 109
Study 20203173 — intervention group
Group type: EXPERIMENTAL
Intervention: Sunitinib (SU) 37.5 mg daily
Number of subjects: 45
Study 20205741 — intervention group
Group type: EXPERIMENTAL
Intervention: Tai Chi exercise (twice weekly for 12 weeks)
Number of subjects: 15
Study 20205824 — intervention group
Group type: EXPERIMENTAL
Intervention: Pay-for-performance (P4P) condition
Number of subjects: 29
Study 20205824 — intervention group
Group type: COMPARATOR
Intervention: Implementation as usual (IAU) condition
Number of subjects: 29
Study 20205864 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly short-time recalls for EBF at week 6
Number of subjects: 30
Study 20205864 — intervention group
Group type: EXPERIMENTAL
Intervention: Recall since-birth for EBF at week 6
Number of subjects: 30
Study 20205864 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly short-time recalls for PBF at week 6
Number of subjects: 30
Study 20205864 — intervention group
Group type: EXPERIMENTAL
Intervention: Recall since-birth for PBF at week 6
Number of subjects: 30
Study 20205864 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly short-time recalls for EBF at week 12
Number of subjects: 30
Study 20205864 — intervention group
Group type: EXPERIMENTAL
Intervention: Recall since-birth for EBF at week 12
Number of subjects: 30
Study 20205864 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly short-time recalls for PBF at week 12
Number of subjects: 30
Study 20205864 — intervention group
Group type: EXPERIMENTAL
Intervention: Recall since-birth for PBF at week 12
Number of subjects: 30
Study 20206456 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosuvastatin 20 mg
Number of subjects: 3267
Study 20206456 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3267
Study 20206940 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous ECG monitoring during PICC insertion
Number of subjects: 6
Study 20207638 — intervention group
Group type: EXPERIMENTAL
Intervention: Sacral nerve stimulation (SNS)
Number of subjects: 62
Study 20208057 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose chloroquine
Number of subjects: 0
Study 20208057 — intervention group
Group type: COMPARATOR
Intervention: Saline
Number of subjects: 0
Study 20210522 — intervention group
Group type: COMPARATOR
Intervention: Basal Cell Carcinomas (BCC)
Number of subjects: 28
Study 20210522 — intervention group
Group type: COMPARATOR
Intervention: Squamous Cell Carcinomas (SCC)
Number of subjects: 28
Study 20210522 — intervention group
Group type: COMPARATOR
Intervention: Premalignant Actinic Keratoses (AK)
Number of subjects: 28
Study 20210522 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthy Controls
Number of subjects: 28
Study 20210645 — intervention group
Group type: EXPERIMENTAL
Intervention: 7-valent pneumococcal conjugate vaccine (PCV) prime at week 0 followed by a 23-valent pneumococcal polysaccharide vaccine (PPV) boost at week 4
Number of subjects: 0
Study 20210645 — intervention group
Group type: COMPARATOR
Intervention: PPV alone
Number of subjects: 0
Study 20211302 — intervention group
Group type: EXPERIMENTAL
Intervention: Any beta-blocker for patients with LVSD
Number of subjects: 20441
Study 20211302 — intervention group
Group type: EXPERIMENTAL
Intervention: Evidence-based beta-blocker for patients with LVSD
Number of subjects: 20441
Study 20211302 — intervention group
Group type: EXPERIMENTAL
Intervention: Warfarin for patients with atrial fibrillation
Number of subjects: 20441
Study 20211302 — intervention group
Group type: EXPERIMENTAL
Intervention: Aldosterone antagonist for patients with LVSD
Number of subjects: 20441
Study 20211302 — intervention group
Group type: EXPERIMENTAL
Intervention: Implantable cardioverter-defibrillator for patients with ejection fraction ≤35%
Number of subjects: 20441
Study 20211302 — intervention group
Group type: EXPERIMENTAL
Intervention: Referral to disease management
Number of subjects: 20441
Study 20211560 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral masitinib at 7.5mg/kg/d
Number of subjects: 30
Study 20211892 — intervention group
Group type: EXPERIMENTAL
Intervention: Doripenem
Number of subjects: 1830
Study 20211892 — intervention group
Group type: COMPARATOR
Intervention: Comparators
Number of subjects: 1830
Study 20212194 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreous dexamethasone
Number of subjects: 0
Study 20214479 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary vaccination
Number of subjects: 0
Study 20214479 — intervention group
Group type: COMPARATOR
Intervention: Revaccination
Number of subjects: 0
Study 20214527 — intervention group
Group type: EXPERIMENTAL
Intervention: Lapatinib monotherapy
Number of subjects: 33
Study 20214665 — intervention group
Group type: EXPERIMENTAL
Intervention: Mannitol challenge
Number of subjects: 61
Study 20214665 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise test
Number of subjects: 61
Study 20214665 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorine exposure
Number of subjects: 61
Study 20214798 — intervention group
Group type: EXPERIMENTAL
Intervention: Additional parenteral nutrition (APN)
Number of subjects: 32
Study 20215446 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin treatment
Number of subjects: 137
Study 20215456 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive glycemia treatment
Number of subjects: 10251
Study 20215456 — intervention group
Group type: COMPARATOR
Intervention: Standard glycemia treatment
Number of subjects: 10251
Study 20215923 — intervention group
Group type: EXPERIMENTAL
Intervention: Lisdexamfetamine dimesylate (LDX) treatment
Number of subjects: 281
Study 20215935 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy (COMB)
Number of subjects: 427
Study 20215935 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine (FLX)
Number of subjects: 427
Study 20215935 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT)
Number of subjects: 427
Study 20215935 — intervention group
Group type: EXPERIMENTAL
Intervention: Placebo (PBO)
Number of subjects: 427
Study 20216101 — intervention group
Group type: EXPERIMENTAL
Intervention: Food allergy screening (skin prick, atopy patch, serum-specific IgE, IgG, IgG4 testing)
Number of subjects: 22
Study 20216101 — intervention group
Group type: COMPARATOR
Intervention: Skin prick, atopy patch, and serum-specific testing
Number of subjects: 22
Study 20216101 — intervention group
Group type: EXPERIMENTAL
Intervention: Receiver operating characteristics curves for SIgG and SIgG4
Number of subjects: 22
Study 20219110 — intervention group
Group type: EXPERIMENTAL
Intervention: Pneumococcal polysaccharide vaccine (PPV)
Number of subjects: 0
Study 20219965 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-year lifestyle intervention
Number of subjects: 663
Study 20220059 — intervention group
Group type: EXPERIMENTAL
Intervention: (R)VAD+C regimen
Number of subjects: 113
Study 20220059 — intervention group
Group type: COMPARATOR
Intervention: MIPI score
Number of subjects: 113
Study 20220059 — intervention group
Group type: COMPARATOR
Intervention: Ki67
Number of subjects: 113
Study 20220059 — intervention group
Group type: COMPARATOR
Intervention: Prognostic scoring system
Number of subjects: 113
Study 20220062 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) before treatment (day 0) and on day 7 after induction chemotherapy
Number of subjects: 80
Study 20221623 — intervention group
Group type: COMPARATOR
Intervention: Photodynamic therapy with verteporfin alone (PDT)
Number of subjects: 45
Study 20221623 — intervention group
Group type: EXPERIMENTAL
Intervention: Photodynamic therapy combined with intravitreal bevacizumab (COMB)
Number of subjects: 45
Study 20222977 — intervention group
Group type: EXPERIMENTAL
Intervention: Canfosfamide plus pegylated liposomal doxorubicin (PLD) at 960/50 mg/m2
Number of subjects: 39
Study 20223916 — intervention group
Group type: EXPERIMENTAL
Intervention: Caucasian ethnicity
Number of subjects: 1010
Study 20223916 — intervention group
Group type: EXPERIMENTAL
Intervention: European ancestry
Number of subjects: 1010
Study 20223916 — intervention group
Group type: EXPERIMENTAL
Intervention: West African ancestry
Number of subjects: 1010
Study 20225395 — intervention group
Group type: EXPERIMENTAL
Intervention: Algorithm for identifying risk of myocardial ischaemia
Number of subjects: 305
Study 20225992 — intervention group
Group type: EXPERIMENTAL
Intervention: Monthly intravenous C.E.R.A.
Number of subjects: 424
Study 20226028 — intervention group
Group type: EXPERIMENTAL
Intervention: Heavy ion therapy (HIT) with a target dose of 60-66 Gy E, including 45 Gy PT and a carbon ion boost of 15-21 Gy E, administered weekly in fractions of 5-6 x 3 Gy E
Number of subjects: 0
Study 20228610 — intervention group
Group type: EXPERIMENTAL
Intervention: CIMT measurements in FH patients
Number of subjects: 1624
Study 20228610 — intervention group
Group type: EXPERIMENTAL
Intervention: CIMT measurements in MD patients
Number of subjects: 1624
Study 20228610 — intervention group
Group type: COMPARATOR
Intervention: Body mass index and waist circumference in FH patients
Number of subjects: 1624
Study 20228610 — intervention group
Group type: COMPARATOR
Intervention: Waist circumference in MD patients
Number of subjects: 1624
Study 20228610 — intervention group
Group type: COMPARATOR
Intervention: Segment-specific completeness in FH patients
Number of subjects: 1624
Study 20228610 — intervention group
Group type: COMPARATOR
Intervention: Segment-specific completeness in MD patients
Number of subjects: 1624
Study 20230209 — intervention group
Group type: EXPERIMENTAL
Intervention: IV esomeprazole 40 mg twice daily for 48 hours (can continue for another 24 hours if no prepyloric enteral feedings planned)
Number of subjects: 44
Study 20230418 — intervention group
Group type: EXPERIMENTAL
Intervention: Outpatient treatment of acute pulmonary embolism with low NT-proBNP levels (< 500 pg mL(-1)).
Number of subjects: 152
Study 20230622 — intervention group
Group type: EXPERIMENTAL
Intervention: Adalimumab 40 mg every other week
Number of subjects: 1250
Study 20230905 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxyurea therapy
Number of subjects: 105
Study 20231152 — intervention group
Group type: EXPERIMENTAL
Intervention: Automatic capture management (CM)
Number of subjects: 160
Study 20231202 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-reported outcomes (PRO) - TJ global score on a 100-mm VAS
Number of subjects: 66
Study 20231202 — intervention group
Group type: COMPARATOR
Intervention: Physical examination measures (TJ swelling, TJ tenderness)
Number of subjects: 66
Study 20231206 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunosuppressive therapy
Number of subjects: 42
Study 20231206 — intervention group
Group type: COMPARATOR
Intervention: No immunosuppressive therapy
Number of subjects: 42
Study 20231206 — intervention group
Group type: EXPERIMENTAL
Intervention: SLE patients
Number of subjects: 42
Study 20231595 — intervention group
Group type: EXPERIMENTAL
Intervention: Desired position of the eyebrows in women
Number of subjects: 40